drugset / Trial / NCT00550147

Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior.

NCT00550147

Phase 2 Completed 30 enrolled Indiana University
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this thirteen-week, open-label study is to test the hypothesis that quetiapine in combination with Oros methylphenidate will reduce aggressive symptoms in children and adolescents who have shown inadequate response to OROS methylphenidate alone.

Timeline

Start
2004-02
Primary completion
2005-11
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylphenidate Small molecule 54 mg
Subject Quetiapine Small molecule 25 mg
Subject Quetiapine Small molecule 50 mg
Subject Quetiapine Small molecule 100 mg
Subject Quetiapine Small molecule 200 mg
Subject Quetiapine Small molecule 300 mg